Safety and Efficacy of Saracatinib In Subjects With Lymphangioleiomyomatosis
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Daniel Dilling, MD
Loyola University
Principal Investigator - Francis X McCormack, MD
University of Cincinnati
Principal Investigator - Joel Moss, MD
Laboratory of Translational Research - NHLBI
Principal Investigator - Stephen Ruoss, MD
Stanford University
Principal Investigator - Tony Eissa, MD
Baylor College of Medicine
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Stanford University
Stanford, California, United States
- Loyola Medical Center
Chicago, Illinois, United States
- Laboratory of Translational Research Nhlbi
Bethesda, Maryland, United States
- University of Cincinnati
Cincinnati, Ohio, United States
- Baylor College of Medicine - Ben Taub General Hospital
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Apr 2016
- Primary completion
- 30 Jul 2019
- Completion
- 30 Jul 2019
- Last update posted
- 30 Jul 2020
- Registered enrollment
- 28
- Registry id
- NCT02737202
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.